Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data.

Date publication

décembre 2020

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Dr GRANEL-BROCARD Florence

Tous les auteurs :
Di Filippo Y, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Saiag P, Brunet-Possenti F, Arnnault JP, Maubec E, Granel-Brocard F, De Quatrebarbes J, Aubin F, Lesimple T, Beylot-Barry M, Stoebner PE, Dupuy A, Stephan A, Grob JJ, Lefevre W, Oriano B, Allayous C, Lebbé C, Montaudié H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33385520

Résumé

The "obesity paradox" suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor therapy. Higher BMI is also associated with higher incidences of treatment-related adverse events. This study assesses whether body mass index is associated with survival outcomes and adverse events in metastatic melanoma patients with systemic therapy.

Mots clés

body mass index, clinical outcomes, immunotherapy, melanoma, systemic therapy, targeted therapy

Référence

Ann Oncol. 2020 Dec 29;: